Consensus $4.83. Narrows FY25 revenue view to $4.15B-$4.3B from $4.15B-$4.4B, consensus $4.23B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals reports Q2 adjusted EPS ($8.25), consensus ($6.25)
- 3 “Strong Buy” Growth Stocks to Buy Now, 8/5/2025, According to Analysts
- These 3 Stocks Are Screaming ‘Strong Buy,’ According to the Technical Analysis
- Jazz Pharmaceuticals’ Zanidatamab Study: A Potential Game-Changer in Breast Cancer Treatment
- JAZZ Earnings this Week: How Will it Perform?